Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS XR ODT versus METHYLIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS XR ODT versus METHYLIN ER.
ADZENYS XR-ODT vs METHYLIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adzenys XR-ODT contains amphetamine, a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
Initial: 9.4 mg orally once daily in the morning; titrate in increments of 9.4 mg per week based on tolerability and response. Maximum: 56.4 mg once daily.
20-60 mg orally once daily in the morning
None Documented
None Documented
Approximately 9-14 hours in adults, 8-11 hours in children (6-12 years). Extended-release pharmacokinetics produce a longer clinical duration compared to immediate-release formulations.
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Renal: approximately 90% as unchanged drug and metabolites (30%-40% as amphetamine, 40%-50% as hippuric acid and benzoic acid). Fecal: <4%. Biliary: negligible.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant